118 related articles for article (PubMed ID: 17022147)
21. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.
Tsuda H; Ito YM; Ohashi Y; Wong KK; Hashiguchi Y; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6880-8. PubMed ID: 16203778
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma.
Aoki D; Suzuki N; Susumu N; Noda T; Suzuki A; Tamada Y; Higashiguchi A; Oie S; Nozawa S
Hum Cell; 2005 Sep; 18(3):143-6. PubMed ID: 17022146
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region.
Katabami K; Mizuno H; Sano R; Saito Y; Ogura M; Itoh S; Tsuji T
Clin Exp Metastasis; 2005; 22(7):539-48. PubMed ID: 16475024
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
25. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy.
Matsuura M; Suzuki T; Saito T
Cancer Sci; 2010 Aug; 101(8):1828-33. PubMed ID: 20545695
[TBL] [Abstract][Full Text] [Related]
26. Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
Suzuki N; Yoshioka N; Uekawa A; Matsumura N; Tozawa A; Koike J; Konishi I; Kiguchi K; Ishizuka B
Int J Gynecol Cancer; 2010 Feb; 20(2):212-9. PubMed ID: 20134265
[TBL] [Abstract][Full Text] [Related]
27. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
28. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
29. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.
Okada S; Tsuda H; Takarabe T; Yoshikawa H; Taketani Y; Hirohashi S
Jpn J Cancer Res; 2002 Jul; 93(7):798-806. PubMed ID: 12149146
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.
McDaid HM; Cairns MT; Atkinson RJ; McAleer S; Harkin DP; Gilmore P; Johnston PG
Br J Cancer; 1999 Feb; 79(5-6):933-9. PubMed ID: 10070893
[TBL] [Abstract][Full Text] [Related]
32. BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.
Sellar GC; Li L; Watt KP; Nelkin BD; Rabiasz GJ; Stronach EA; Miller EP; Porteous DJ; Smyth JF; Gabra H
Cancer Res; 2001 Oct; 61(19):6977-81. PubMed ID: 11585719
[TBL] [Abstract][Full Text] [Related]
33. Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.
Okuma Y; Kiguchi K; Koshitaka Y; Okamura A; Ishiwata I; Kondo H; Ishizuka B; Tadokoro M
Hum Cell; 2003 Sep; 16(3):131-9. PubMed ID: 15005244
[TBL] [Abstract][Full Text] [Related]
34. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.
Yamada T; Hattori K; Satomi H; Okazaki T; Mori H; Hirose Y
J Ovarian Res; 2016 Jun; 9(1):32. PubMed ID: 27259990
[TBL] [Abstract][Full Text] [Related]
37. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
38. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail.
Ding JX; Feng YJ; Yao LQ; Yu M; Jin HY; Yin LH
Gynecol Oncol; 2006 Nov; 103(2):623-30. PubMed ID: 16806441
[TBL] [Abstract][Full Text] [Related]
39. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors.
Kyo S; Kanaya T; Takakura M; Tanaka M; Yamashita A; Inoue H; Inoue M
Int J Cancer; 1999 Mar; 80(6):804-9. PubMed ID: 10074910
[TBL] [Abstract][Full Text] [Related]
40. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
